Danaher Co. (NYSE:DHR) CFO Matthew Mcgrew Sells 7,457 Shares
Danaher Co. (NYSE:DHR) CFO Matthew Mcgrew sold 7,457 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $203.42, for a total value of $1,516,902.94. Following the sale, the chief financial officer now owns 12,387 shares of the company’s stock, valued at $2,519,763.54. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
NYSE:DHR opened at $203.80 on Friday. The stock has a market cap of $142.15 billion, a P/E ratio of 43.64, a price-to-earnings-growth ratio of 3.20 and a beta of 0.92. The firm’s fifty day simple moving average is $182.24 and its 200 day simple moving average is $161.95. Danaher Co. has a twelve month low of $119.60 and a twelve month high of $204.13. The company has a quick ratio of 1.74, a current ratio of 2.20 and a debt-to-equity ratio of 0.68.
Danaher (NYSE:DHR) last announced its earnings results on Thursday, July 23rd. The conglomerate reported $1.44 EPS for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.35. Danaher had a net margin of 17.73% and a return on equity of 11.88%. The firm had revenue of $5.30 billion for the quarter, compared to analysts’ expectations of $5.01 billion. During the same quarter in the previous year, the business posted $1.09 EPS. The company’s quarterly revenue was up 2.7% on a year-over-year basis. On average, analysts expect that Danaher Co. will post 5.42 EPS for the current fiscal year.
Several equities research analysts recently weighed in on the company. Credit Suisse Group increased their target price on Danaher from $165.00 to $169.00 and gave the company an “outperform” rating in a report on Thursday, May 21st. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $203.00 target price for the company in a report on Tuesday, July 21st. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $195.00 target price for the company in a report on Tuesday, June 16th. UBS Group increased their target price on Danaher from $176.00 to $233.00 and gave the company a “buy” rating in a report on Monday, July 27th. Finally, Robert W. Baird upped their price target on Danaher from $163.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $197.73.
Hedge funds have recently made changes to their positions in the company. Howe & Rusling Inc. boosted its holdings in shares of Danaher by 81.4% during the 2nd quarter. Howe & Rusling Inc. now owns 156 shares of the conglomerate’s stock valued at $28,000 after buying an additional 70 shares in the last quarter. Lion Street Advisors LLC bought a new stake in shares of Danaher during the 1st quarter valued at $25,000. Semmax Financial Advisors Inc. bought a new stake in shares of Danaher during the 2nd quarter valued at $35,000. Manchester Financial Inc. boosted its holdings in shares of Danaher by 50.0% during the 1st quarter. Manchester Financial Inc. now owns 228 shares of the conglomerate’s stock valued at $32,000 after buying an additional 76 shares in the last quarter. Finally, Trustcore Financial Services LLC boosted its holdings in shares of Danaher by 36.9% during the 2nd quarter. Trustcore Financial Services LLC now owns 230 shares of the conglomerate’s stock valued at $41,000 after buying an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 77.67% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Read More: What is the definition of arbitrage?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.